Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Mavyret Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Mavyret Prior Authorization for Chronic Hepatitis C

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and approval durations for Mavyret in adults with chronic hepatitis C based on genotype, treatment history, fibrosis, cirrhosis status, and specialist prescribing; it also identifies non-approval conditions.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyMavyret Prior Authorization for Chronic Hepatitis C
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateOct 24, 2017
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit pre-authorization for Mavyret with documentation of genotype, treatment history, age, specialist involvement, fibrosis score, liver disease status, and treatment duration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18 yearsMinimum patient age
    ≥2Required fibrosis threshold
    8, 12, or 16 weeksPossible approval durations
    6 genotypesTreatment-naive genotypes addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4 exclusions
    Explicit non-approval conditions

    Coverage Criteria

    Treatment-naive chronic HCV genotype 1-6

    Covered for chronic HCV genotype 1, 2, 3, 4, 5, or 6 in treatment-naive adults when ALL criteria are met.

    Treatment-naive eligibility

    • Duration pathway

      • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
      • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks

    Treatment-experienced genotype 1

    Covered for chronic HCV genotype 1 in treatment-experienced adults when ALL baseline criteria are met and ONE treatment-history pathway applies.

    Genotype 1 treatment-experienced baseline criteria

    • Treatment-history pathways

      • NS5A experienced, NS3/4A naive: Patient had a prior null response, prior partial response, or relapse after treatment with Daklinza or Harvoni; patient has not previously been treated with Olysio, Victrelis, Incivek, Technivie, Viekira-Pak, Viekira XR, Vosevi, or Zepatier; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 16 weeks
      • NS3/4A experienced, NS5A naive: Patient has not previously been treated with Daklinza, Epclusa, Harvoni, Technivie, Viekira-Pak, Viekira XR, Vosevi, or Zepatier; patient had a prior null response, prior partial response, or relapse after treatment with Olysio, Victrelis, or Incivek; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks
      • Pegylated interferon/interferon, ribavirin, or Sovaldi experienced

        • Duration pathway

    Treatment-experienced genotypes 2, 4, 5, and 6

    Covered for chronic HCV genotype 2, 4, 5, or 6 in treatment-experienced adults when ALL criteria are met.

    Treatment-experienced genotype 2, 4, 5, or 6

    • Liver-status pathway

      • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
      • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks

    Treatment-experienced genotype 3

    Covered for chronic HCV genotype 3 in treatment-experienced adults when ALL criteria are met.

    Treatment-experienced genotype 3: Patient is at least 18 years old; Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician; fibrosis score is at least 2; patient had a prior null response, prior partial response, or relapse after treatment with interferon with or without ribavirin, pegylated interferon with or without ribavirin, Sovaldi plus ribavirin, or Sovaldi plus pegylated interferon plus ribavirin; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 16 weeks

    All listed criteria are required.

    Mavyret is not approved for patients with chronic HCV and Child-Pugh Class C liver disease or severe hepatic impairment.

    Mavyret is not approved when HCV treatment is administered in combination with another direct-acting antiviral.

    Mavyret is not approved when the patient has a life expectancy of less than 12 months because of non-liver-related comorbidities.

    Mavyret is not approved for pediatric patients younger than 18 years.

    Initial Therapy Authorization

    Treatment-naive initial therapy

    Initial therapy is covered for treatment-naive adults with chronic HCV genotype 1, 2, 3, 4, 5, or 6 when ALL criteria are met.

    • Liver-status and duration pathway

      • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
      • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks

    Treatment-experienced initial authorization

    Initial authorization for treatment-experienced therapy requires the applicable genotype- and treatment-history-specific pathway. The patient must meet ALL criteria within the applicable pathway.

    Coverage Parameters

    Patient age
    Minimum age≥ 18 years
    Applies toTreatment-naive and treatment-experienced adults with chronic HCV
    Non-approval conditionPediatric patients younger than 18 years
    Fibrosis score
    Required fibrosis score≥ 2
    Treatment-naive pathwayA fibrosis score of ≥ 2 is required for chronic HCV genotype 1, 2, 3, 4, 5, or 6
    Treatment-experienced pathwayA fibrosis score of ≥ 2 is required for the applicable genotype-specific treatment-experienced criteria

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain pre-authorization before prescribing

    Mavyret requires pre-authorization. Submit the request with the patient’s HCV genotype, treatment history, age, specialist involvement, fibrosis score, liver disease status, and applicable treatment duration.

    Documentation Required

    Document clinical eligibility

    Submit documentation of patient age, HCV genotype, treatment-naive or treatment-experienced status, fibrosis score, cirrhosis status including Child-Pugh class where applicable, and the prescribing physician’s or consultant’s specialty.

    • Patient must be at least 18 years of age.
    • Fibrosis score must be ≥ 2.
    • Mavyret must be prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician.

    Medication Background

    Mavyret combines glecaprevir and pibrentasvir as a direct-acting antiviral treatment for chronic hepatitis C virus infection. Glecaprevir inhibits the HCV NS3/4A protease, while pibrentasvir inhibits HCV NS5A; together, these actions disrupt viral replication and virion assembly.

    Clinical Definitions

    Fibrosis score
    Required thresholdFibrosis score of at least 2
    Coverage relevanceRequired for the covered treatment-naive and treatment-experienced pathways described in the policy
    DocumentationSubmit the patient's fibrosis score with the authorization request
    Child-Pugh classification
    Compensated cirrhosisChild-Pugh Class A
    Treatment duration with Class AApprove for 12 weeks when the applicable pathway specifies compensated cirrhosis
    Non-approved disease
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyMavyret Prior Authorization for Chronic Hepatitis C
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateOct 24, 2017
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit pre-authorization for Mavyret with documentation of genotype, treatment history, age, specialist involvement, fibrosis score, liver disease status, and treatment duration.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy AuthorizationCoverage ParametersAuthorization and Documentation RequirementsMedication BackgroundClinical Definitions
    • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
    • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks

    Genotype- and treatment-history-specific pathways

    • Genotype 1: NS5A experienced, NS3/4A naive: Patient has genotype 1; is at least 18 years old; Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician; fibrosis score is at least 2; patient had a prior null response, prior partial response, or relapse after Daklinza or Harvoni; patient has not previously been treated with Olysio, Victrelis, Incivek, Technivie, Viekira-Pak, Viekira XR, Vosevi, or Zepatier; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 16 weeks
    • Genotype 1: NS3/4A experienced, NS5A naive: Patient has genotype 1; is at least 18 years old; Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician; fibrosis score is at least 2; patient has not previously been treated with Daklinza, Epclusa, Harvoni, Technivie, Viekira-Pak, Viekira XR, Vosevi, or Zepatier; patient had a prior null response, prior partial response, or relapse after Olysio, Victrelis, or Incivek; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks
    • Genotype 1: pegylated interferon/interferon, ribavirin, or Sovaldi experienced

      • Duration pathway

        • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
        • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks
    • Genotype 2, 4, 5, or 6

      • Liver-status pathway

        • No cirrhosis: Patient does not have cirrhosis.Approve for 8 weeks
        • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Approve for 12 weeks
    • Genotype 3: Patient has genotype 3; is at least 18 years old; Mavyret is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease physician, or liver transplant physician; fibrosis score is at least 2; patient had a prior null response, prior partial response, or relapse after interferon with or without ribavirin, pegylated interferon with or without ribavirin, Sovaldi plus ribavirin, or Sovaldi plus pegylated interferon plus ribavirin; and patient does not have cirrhosis or has compensated cirrhosis (Child-Pugh A).Approve for 16 weeks
    Treatment duration
    Without cirrhosis8 weeks
    Compensated cirrhosis12 weeks for Child-Pugh Class A
    Specified experienced-treatment pathways16 weeks for genotype 1 NS5A-experienced/NS3/4A-naive treatment and genotype 3 treatment-experienced therapy
    Documentation Required

    Provide complete prior-treatment history

    For treatment-experienced requests, document the prior regimen or product, whether the patient had a prior null response, partial response, or relapse, and any prior exposure or non-exposure required by the applicable treatment pathway.

    • Identify the prior regimen or product.
    • Document the prior treatment response or relapse.
    • Document required prior exposure or non-exposure for the applicable genotype-specific pathway.
    Denial Risk

    Screen for non-approval conditions

    Mavyret is not to be approved for the following conditions: HCV Child-Pugh Class C liver disease or severe hepatic impairment; HCV treatment in combination with any other direct-acting antiviral; life expectancy of less than 12 months due to non-liver-related comorbidities; or pediatric patients younger than 18 years.

    • Child-Pugh Class C liver disease or severe hepatic impairment.
    • Combination treatment with another direct-acting antiviral.
    • Life expectancy less than 12 months due to non-liver-related comorbidities.
    • Pediatric age younger than 18 years.
    Denial Risk

    Meet all applicable clinical criteria

    Requests must satisfy the applicable genotype- and treatment-history-specific criteria, including specialist prescribing or consultation, fibrosis score of at least 2, qualifying prior treatment history when treatment experienced, and the required cirrhosis or Child-Pugh status. Failure to document all applicable criteria may result in non-approval.

    • Apply the pathway for the patient’s HCV genotype and treatment history.
    • Confirm age ≥18 years and fibrosis score ≥2.
    • Confirm prescribing by or consultation with a qualified specialist.
    • Document the required cirrhosis or Child-Pugh status and applicable treatment duration.
    Child-Pugh Class C liver disease, also described as severe hepatic impairment, is not approved